CorMedix Inc.
CorMedix Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) on January 15, 2028. There are 2 upcoming events on record.
CorMedix Inc. generates cash from operations, so a burn-based runway figure does not apply.
| Date | Event | Type | Phase |
|---|---|---|---|
| January 15, 2028 | Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) | Trial Milestone | Phase 3 |
| July 15, 2028 | Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age | Trial Milestone | Phase 4 |
Track CRMD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CRMD in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.